

## LISTING OF THE CLAIMS

Claims 1-45 (Canceled).

Claim 46. (Currently Amended). ~~An oral~~ pharmaceutical composition comprising ~~a daily dose of a valproate compound~~ divalproex sodium, wherein the composition, when ~~provided~~ administered once a day ~~to a patient, to a steady state population of patients, provides an~~ follows a zero-order release pattern thus producing essentially flat plasma levels that average pharmacokinetic curve such that the plasma concentration levels vary within a range of about 30 µg/ml, when determined at a steady state in a healthy fasting population.

Claim 47. (Canceled).

Claim 48. (Currently Amended). The composition of claim 46 wherein the flat ~~average pharmacokinetic maintains a plasma level of~~ plasma levels maintain valproate within a therapeutic range.

Claim 49. (Canceled).

Claim 50. (Canceled).

Claim 51. (Currently Amended). The composition of claim ~~46~~ 47 wherein the composition further provides a mean steady-state  $AUC_{0-24}$  measurement of valproate that is at least 80% of the mean steady-state  $AUC_{0-24}$  measurement of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 52. (Previously Presented). The composition of claim 51 wherein the composition further provides a mean steady-state  $C_{max}$  of valproate that is statistically significantly lower than the mean steady-state  $C_{max}$  of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 53. (Previously Presented). The composition of claim 52 wherein the mean steady-state degree of fluctuation of valproate provided by the composition is less than the mean steady-state degree of fluctuation of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 54. (Previously Presented). The composition of claim 53 wherein the mean steady-state Tmax of valproate provided by the composition is at least twice as long as the mean steady-state Tmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 55. (Previously Presented). The composition of claim 54 wherein the mean steady-state Cmin of valproate provided by the composition is not statistically different than the mean steady-state Cmin of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 56. (Currently Amended). ~~An oral~~ pharmaceutical composition comprising ~~a daily dose of a valproate compound~~ divalproex sodium, wherein the composition, when ~~provided~~ administered once a day ~~to a patient, to a steady state population of patients,~~ provides a mean Cmin of about 48 or higher, when determined at a steady state in a healthy fasting population.

Claim 57. (Canceled).

Claim 58 (Currently Amended). The pharmaceutical composition of claim ~~56~~ 57 wherein the composition further provides an essentially flat average pharmacokinetic curve such that the plasma concentration levels vary within a range of about 30 µg/ml.

Claim 59. (Canceled).